Company profile
Pharming Group N.V.
NASDAQ:PHARBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| LENIOLISIB PHOSPHATE | approved | — | 3 | approved |
| Napazimone | phase2 | — | 1 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (20)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02247739 | phase2 | completed | 2014-12-01 | 2016-05-01 | Pharming Technologies B.V. | A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor |
| NCT00851409 | phase2 | completed | 2009-06-01 | 2010-03-01 | Pharming Technologies B.V. | A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration |
| NCT06249997 | phase3 | unknown | 2023-08-03 | 2025-01-31 | Pharming Technologies B.V. | An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS |
| NCT05650229 | phase2 | recruiting | 2022-12-13 | 2027-10-01 | Pharming Technologies B.V. | Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease |
| NCT01188564 | phase3 | completed | 2011-01-01 | 2012-12-01 | Pharming Technologies B.V. | Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks |
FDA applications (2)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 125495 | BLA | Pharming Americas BV | ||||
Loading… | ||||||
| NDA 217759 | NDA | PHARMING TECHNOLOGIES BV | ||||
Loading… | ||||||